Clinical Trial Update: A Study of NGM621 in Participants With Geographic Atrophy [Phase 2]

View source ↗

Summary

Phase 2 study of NGM621 for geographic atrophy has completed with results posted on 2025-07-01.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Geographic Atrophy

Drugs mentioned

• NGM621 (NGM621)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Geographic Atrophy | Phase 2 | Status: COMPLETED | Results posted: 2025-07-01